Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.
The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.
The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.
Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.
Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.
Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.
In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.
Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.
A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.
A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.
Adding abiraterone acetate plus prednisone to androgen deprivation therapy continues to provide an overall survival advantage in the first-line treatment of men with high-risk metastatic castration-sensitive prostate cancer, report the LATITUDE investigators.
The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.
Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.
Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.
Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.
Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.
Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.
Patients who receive carbon ion radiotherapy for localized prostate cancer have a significantly lower risk for subsequent primary cancers than those treated with photon radiotherapy or surgery, retrospective study data suggest.